Gennvax noue des alliances stratégiques mondiales pour renforcer l’autonomie vaccinale de l’Égypte

28 juin, 2025

Gennvax Egypt has signed a toll manufacturing agreement with Vacsera for the local production of the PCV13 conjugate vaccine in bulk, ready-to-fill form. This marks the first phase of a comprehensive technology transfer agreement between Gennvax and Minhai, one of China’s leading vaccine manufacturers, extending up to the upstream production stage. Additionally, under the terms of the signed agreement, Minhai has granted Gennvax the rights to export the vaccine to African markets, reinforcing Gennvax’s commitment to expanding access to high-quality vaccines across the continent.

1^st Agreement:

Toll manufacturing agreement with Vacsera

2^nd Agreement:

localization agreement with AJ VACCINES

Gennvax has signed a strategic agreement with AJ Vaccines, a leading Danish biopharmaceutical company, a technology transfer agreement to start as a first phase by the supply of bulk ready-to-fill inactivated polio vaccine (IPV - Salk). The agreement was signed in the presence of Dr. Hesham Sayed Setat, Head of the Egyptian Authority for Unified Procurement (UPA); the Chargé d’Affaires of the Danish Embassy in Egypt; Dr. Nibal Dahaba, Co-founder and General Manager of Gennvax; and Mr. Ole , CEO of AJ Vaccines. This collaboration represents a key milestone in the broader technology transfer agreement between both parties, and includes provisions for export to African markets, reinforcing Gennvax’s role in advancing local manufacturing and regional vaccine accessibility.

3^ed Agreement:

localization agreement with ZYDUS

Gennvax Expands Strategic Collaboration with Zydus to Strengthen Vaccine Supply in Egypt and Africa

Gennvax has signed an expansion to its collaboration agreement with Zydus, one of India’s leading pharmaceutical companies, to enhance regional vaccine access and manufacturing capabilities. The amended agreement activates the supply of bulk ready-to-fill bulk for inactivated vaccines and introduces secondary packaging services for live attenuated vaccines. Additionally, the contract’s territorial scope has been extended from Egypt to include the entire African continent.

This expanded partnership covers six essential vaccines and sera:

• Rabies vaccine (one of only three WHO-prequalified rabies vaccines globally)
• MMR (Measles, Mumps, Rubella)
• MR (Measles, Rubella)
• Tetanus-Diphtheria
• Typhoid
• Bivalent Monoclonal antibodies – Rabies

The agreement was signed in the presence of Dr. Hesham Setaat, Head of the Egyptian Authority for Unified Procurement (UPA); the Ambassador of India to Egypt; the Global Commercial Head of Zydus; and Dr. Nibal Dahaba, Co-founder and General Manager of Gennvax.

This milestone reflects Gennvax’s ongoing commitment to strengthening vaccine self-reliance in Egypt and Africa, leveraging strategic partnerships to ensure sustainable and equitable access to life-saving immunizations.

Étiquettes